(RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled ...

It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known whether it’s ...

Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After ...

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Biotech major Amgen, Inc.AMGN announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU. The submissions seek to include data from a phase III ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...

AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...

Amgen's Fourier outcomes trial showed Repatha slashing heart attack and stroke risks—and, importantly, "proves that [LDL cholesterol] is a poison, like tobacco," its global development chief said. () ...

Amgen’s (AMGN) worst-case scenario from the outcomes trial of Repatha can be dismissed. The California-based group says the cholesterol-lowering jab reduced risk of heart attacks, strokes and ...

(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.